Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines
Neill Horley, Kenneth J. M. Beresford, Tarun Chawla, et al.
European Journal of Medicinal Chemistry (2017) Vol. 129, pp. 159-174
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer
Congcong Chen, Yabing Yang, Yanguan Guo, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 4
Open Access | Times Cited: 47
Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review
Basma Hossam Abdelmonem, Noha M. Abdelaal, Eman K. E. Anwer, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1467-1467
Open Access | Times Cited: 16
Involvement of cytochrome P450 enzymes in inflammation and cancer: a review
Maria Carolina Stipp, Alexandra Acco
Cancer Chemotherapy and Pharmacology (2020) Vol. 87, Iss. 3, pp. 295-309
Closed Access | Times Cited: 85
Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes
Yurong Song, Chenxi Li, Guangzhi Liu, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 5, pp. 585-601
Closed Access | Times Cited: 66
Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes
Yeo‐Jung Kwon, Sangyun Shin, Young‐Jin Chun
Archives of Pharmacal Research (2021) Vol. 44, Iss. 1, pp. 63-83
Closed Access | Times Cited: 55
Ru(II) photocages enable precise control over enzyme activity with red light
Dmytro Havrylyuk, Austin C. Hachey, Alexander D. Fenton, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 45
Heme-thiolate monooxygenase cytochrome P450 1B1, an old dog with many new tricks
Jong-Won Kim, Hung‐Chun Tung, Bin Yang, et al.
Pharmacological Reviews (2025) Vol. 77, Iss. 3, pp. 100045-100045
Closed Access
Lymphovascular invasion is associated with doxorubicin resistance in breast cancer
Allen Joy M. Corachea, Regina Joyce E Ferrer, Lance Patrick B Ty, et al.
Laboratory Investigation (2025), pp. 104115-104115
Closed Access
Inhibitors of cytochrome P450 (CYP) 1B1
Raphaël Dutour, Donald Poirier
European Journal of Medicinal Chemistry (2017) Vol. 135, pp. 296-306
Closed Access | Times Cited: 55
Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance
Ibidapo S. Williams, Prashant Joshi, Linda Gatchie, et al.
Bioorganic & Medicinal Chemistry Letters (2017) Vol. 27, Iss. 16, pp. 3683-3687
Open Access | Times Cited: 52
Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it
Himanshu Verma, Malkeet Singh Bahia, Shalki Choudhary, et al.
Drug Metabolism Reviews (2019) Vol. 51, Iss. 2, pp. 196-223
Closed Access | Times Cited: 47
Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification
Ying Wang, Xiaomei He, Chunshi Li, et al.
European Journal of Medicinal Chemistry (2020) Vol. 193, pp. 112235-112235
Closed Access | Times Cited: 40
A 1,2,3-Triazole Derivative of Quinazoline Exhibits Antitumor Activity by Tethering RNF168 to SQSTM1/P62
Fu-Cheng Wang, Bin Peng, Ting-Ting Ren, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 22, pp. 15028-15047
Closed Access | Times Cited: 22
Mitochondrial cytochrome P450 (CYP) 1B1 is responsible for melatonin‐induced apoptosis in neural cancer cells
Zhenlong Yu, Xiangge Tian, Yuling Peng, et al.
Journal of Pineal Research (2018) Vol. 65, Iss. 1
Closed Access | Times Cited: 44
Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme
Rajni Sharma, Linda Gatchie, Ibidapo S. Williams, et al.
Bioorganic & Medicinal Chemistry Letters (2017) Vol. 27, Iss. 24, pp. 5400-5403
Closed Access | Times Cited: 40
Identification of Potent and Selective CYP1A1 Inhibitors via Combined Ligand and Structure-Based Virtual Screening and Their in Vitro Validation in Sacchrosomes and Live Human Cells
Prashant Joshi, Glen J. P. McCann, Vinay R. Sonawane, et al.
Journal of Chemical Information and Modeling (2017) Vol. 57, Iss. 6, pp. 1309-1320
Closed Access | Times Cited: 39
CYP1B1 gene: Implications in glaucoma and cancer
Arwa Alsubait, Wadha Aldossary, Mamoon Rashid, et al.
Journal of Cancer (2020) Vol. 11, Iss. 16, pp. 4652-4661
Open Access | Times Cited: 38
CYP1B1 as a therapeutic target in cardio-oncology
Alexa N. Carrera, Marianne Grant, Beshay N. Zordoky
Clinical Science (2020) Vol. 134, Iss. 21, pp. 2897-2927
Open Access | Times Cited: 30
Scaffold hopping for designing of potent and selective CYP1B1 inhibitors to overcome docetaxel resistance: synthesis and evaluation
Baddipadige Raju, Gera Narendra, Himanshu Verma, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-19
Closed Access | Times Cited: 2
Development of Novel N-Aryl-2,4-bithiazole-2-amine-Based CYP1B1 Degraders for Reversing Drug Resistance
Xiaoxuan Yao, Jianping Mao, Haoyu Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116488-116488
Closed Access | Times Cited: 2
Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[h]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer
Jinyun Dong, Yulong Li, Zhiyuan Jin, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 114, pp. 117944-117944
Closed Access | Times Cited: 2
Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents
Jinyun Dong, G. Huang, Qijing Zhang, et al.
MedChemComm (2019) Vol. 10, Iss. 9, pp. 1606-1614
Open Access | Times Cited: 24
Anticancer Active Heterocyclic Chalcones: Recent Developments
Prasad Dandawate, Khursheed Ahmed, Subhash Padhyé, et al.
Anti-Cancer Agents in Medicinal Chemistry (2020) Vol. 21, Iss. 5, pp. 558-566
Closed Access | Times Cited: 22
Multiple machine learning, molecular docking, and ADMET screening approach for identification of selective inhibitors of CYP1B1
Baddipadige Raju, Himanshu Verma, Gera Narendra, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 17, pp. 7975-7990
Closed Access | Times Cited: 19
Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and miR-27b-3p Down-Regulation through Extracellular Vesicles
Rossana Franzin, Alessandra Stasi, Giuseppe De Palma, et al.
Cells (2023) Vol. 12, Iss. 12, pp. 1655-1655
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top